According to filings with the U.S. Securities and Exchange Commission, Quantum Surgical is raising up to $67,989,800.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Quantum Surgical
Quantum Surgical is a French company founded in Montpellier, France, speacialized in medical robotics and AI. Its Epione robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide. Co-founded in 2017 and with a team of 110+ employees, Quantum Surgical is based in Montpellier, with offices in Miami, Florida. Quantum Surgical received the Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.

To learn more about Quantum Surgical, visit https://www.quantumsurgical.com/
Quantum Surgical Linkedin Page: https://www.linkedin.com/company/quantumsurgical/

Contact:
Christophe Sibillin, Chief Financial Officer
305-913-2400
https://www.linkedin.com/in/christophe-sibillin-03957536/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.